Novartis adds Qualcomm to its list of trial partners

Novartis ($NVS), in the midst of a long-running effort to make clinical trials more efficient, has recruited Qualcomm ($QCOM) to help it gather and store patient data from medical devices. Under the deal, Qualcomm will provide its 2net platform to Novartis, allowing the drugmaker to continually monitor the biometrics of clinical trial participants, storing data in a cloud-based system. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.